Agitation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Agitation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer’s disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-dextromethorphan-deramciclane-fumarate-and-deramciclane-in-treating-agitation-in-people-with-alzheimer-s-disease/ Thu, 30 Apr 2026 13:08:55 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-dextromethorphan-deramciclane-fumarate-and-deramciclane-in-treating-agitation-in-people-with-alzheimer-s-disease/ This study is being conducted to evaluate the safety and effectiveness of two experimental medications, EXV-802 and EXV-801, for treating agitation in individuals living with Alzheimer’s disease dementia. Agitation refers to feelings of restlessness, irritability, or anxious behavior that can occur in people with this type of memory-related brain disorder. The medication EXV-802 contains a combination of dextromethorphan and deramciclane fumarate, while EXV-801 contains deramciclane. Participants in the study may receive one of these active treatments or a placebo.

The study follows a double-blind design, which means that neither the participants nor the researchers know who is receiving the active medication and who is receiving the placebo. This method is used to prevent bias in the results. During the course of the study, participants will take an oral capsule for a period of time to monitor how the medications affect their symptoms and general well-being.

]]> Study on Dexmedetomidine, Midazolam, and Lorazepam for Treating Acute Agitation in Emergency Psychiatry Patients https://clinicaltrials.eu/trial/study-on-dexmedetomidine-midazolam-and-lorazepam-for-treating-acute-agitation-in-emergency-psychiatry-patients/ Wed, 29 Apr 2026 14:28:39 +0000 https://clinicaltrials.eu/trial/study-on-dexmedetomidine-midazolam-and-lorazepam-for-treating-acute-agitation-in-emergency-psychiatry-patients/ This clinical trial is focused on improving the treatment and care for people experiencing acute agitation in emergency psychiatric settings. Acute agitation is a state of extreme restlessness and emotional disturbance that can occur in individuals with psychiatric conditions. The study will compare the effectiveness of three different medications in calming patients: dexmedetomidine (known as Igalmi), lorazepam (known as Lorazepam Orion), and midazolam (known as Midazolam Medical Valley). Dexmedetomidine is administered as a sublingual film, which means it dissolves under the tongue. Lorazepam is taken orally in tablet form, and midazolam is given as an oromucosal solution, which is absorbed through the lining of the mouth.

The purpose of the study is to evaluate how well these medications work in calming patients who are experiencing acute agitation. Participants will receive a single dose of one of the medications, and their level of agitation will be monitored over a period of time. The study aims to determine which medication is most effective in reducing agitation quickly and safely. The trial will also assess how satisfied patients are with the treatment they receive.

Throughout the study, participants will be observed to see how quickly they become calm or fall asleep after taking the medication. The need for additional medication or physical restraint will also be recorded. This research is important for finding the best ways to manage acute agitation in emergency psychiatric care, ensuring that patients receive the most effective and comfortable treatment possible.

]]>